Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genetic and Environmental Factors in the Response to Influenza Vaccination
NCT03088904Phase 1Completed
- Sponsor
- Stanford University
- Start
- Oct 2014
- Primary completion
- Dec 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated) and live attenuated influenza vaccine in influenza (3 arms), sponsored by Stanford University. Primary endpoints: Hemagglutination inhibition titers at Day 28, Interferon-gamma production by T cells at Day 28 and 1 more. Started Oct 2014; status: completed.
02
Drugs
Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (formaldehyde inactivated)live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03088904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03088904.